SCHEMBL30723191

SCHEMBL30723191

Fc1ccccc1-c1ccc(-c2cnc3cc(Cl)ccc3n2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.57
RAB9A P51151 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
TLR9 Q9NR96 1/20 0.47
KDR P35968 2/20 0.44
ADORA3 P0DMS8 1/20 0.44
FGFR3 P22607 1/20 0.44
BCHE P06276 1/20 0.43
MAPK1 P28482 1/20 0.43
APEX1 P27695 2/20 0.42
AURKA O14965 1/20 0.42
AURKB Q96GD4 1/20 0.42
PDGFRB P09619 1/20 0.42
FLT3 P36888 1/20 0.42
ALOX5AP P20292 1/20 0.42
FEN1 P39748 1/20 0.42
BACE1 P56817 1/20 0.42
PIK3R1 P27986 1/20 0.40
PIK3CA P42336 1/20 0.40
MAP4K4 O95819 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21793869 1.00 NPC1 (0.57) NPC1RAB9ASMN1; SMN2TLR9KDR
SCHEMBL15850502 0.84 NPC1 (0.68) NPC1RAB9ASMN1; SMN2TLR9KDR
SCHEMBL30107670 0.84 NPC1 (0.68) NPC1RAB9ASMN1; SMN2TLR9KDR
SCHEMBL21777625 0.83 NPC1 (0.68) NPC1RAB9ASMN1; SMN2TLR9KDR
SCHEMBL31503559 0.82 SMN1; SMN2 (0.67) NPC1RAB9ASMN1; SMN2TLR9KDR
SCHEMBL28534153 0.82 SMN1; SMN2 (0.67) NPC1RAB9ASMN1; SMN2TLR9KDR
SCHEMBL21793877 0.81 NPC1 (0.57) NPC1RAB9ASMN1; SMN2TLR9KDR
SCHEMBL30723189 0.81 NPC1 (0.57) NPC1RAB9ASMN1; SMN2TLR9KDR
SCHEMBL30665751 0.77 BCHE (0.63) NPC1RAB9ASMN1; SMN2TLR9KDR
SCHEMBL27323740 0.77 BCHE (0.63) NPC1RAB9ASMN1; SMN2TLR9KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240156872-A1 Use of Chaperone-Mediated Autophagy Activators For Treating Or Preventing Blood Cancers And Myelodysplastic Syndromes And Enriching Hematopoietic Stem Cell Populations ALBERT EINSTEIN COLLEGE OF MEDICINE 2024-05-16 US disclosed
US-11834424-B2 Compounds useful as chaperone-mediated autophagy modulators ALBERT EINSTEIN COLLEGE OF MEDICINE (US) 2023-12-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11834424-B2 Compounds useful as chaperone-mediated autophagy modulators SQSTM1, HSPA5, ATG7 NPC1 151/4885RAB9A 299/4885SMN1; SMN2 2417/4885
US-20240156872-A1 Use of Chaperone-Mediated Autophagy Activators For Treating Or Preventing Blood Cancers And Myelodysplastic Syndromes And Enriching Hematopoietic Stem Cell Populations SQSTM1, MCL1, HSPA2 NPC1 1454/4885RAB9A 701/4885SMN1; SMN2 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.